Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

This study has been completed.
Sponsor:
Information provided by:
Newron Sweden AB
ClinicalTrials.gov Identifier:
NCT01187966
First received: May 31, 2010
Last updated: August 23, 2010
Last verified: August 2010
  Purpose

The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations who are currently receiving a stable dose of levodopa.


Condition Intervention Phase
Parkinson's Disease
Drug: Safinamide
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic

Resource links provided by NLM:


Further study details as provided by Newron Sweden AB:

Primary Outcome Measures:
  • Increase in mean daily "on" time [ Time Frame: baseline to endpoint ] [ Designated as safety issue: No ]
    Increase in mean daily "on" time ("on" time without dyskinesia plus "on" time with minor dyskinesia) during 18-hr diary recording period


Secondary Outcome Measures:
  • Decrease in total daily "off" time [ Time Frame: baseline to endpoint ] [ Designated as safety issue: No ]
    Decrease in total daily "off" time, UPDRS Section III during "on" phase (based on diary) - mean change from baseline to endpoint, CGI - Change from baseline - mean score in the course of the study, change in cognition (cognitive test battery), decrease in mean "off" time following first morning dose of levodopa, improvement in the Dyskinesias Rating Scale during "on" phase, UPDRS Section II during "on" phase (based on diary),CGI- Severity of illness - mean change from baseline to endpoint, mean percent change in levodopa dose


Enrollment: 669
Study Start Date: January 2007
Study Completion Date: February 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Drug: Placebo
Drug: Placebo
Experimental: High Dose (100mg/day) Drug: Safinamide
Experimental: Low dose (50mg/day) Drug: Safinamide

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients are male or female, age 30-80 years, inclusive. If female, they must be either post-menopausal for at least 12 months, surgically sterilized or have undergone hysterectomy. Patients older than 80 years, who meet all other entry criteria, will be considered for enrollment, with approval of the Newron Medical Expert.
  • Patients must have a diagnosis of idiopathic Parkinson's disease of more than 5 years duration; the diagnosis should be based on medical history and neurological examination. Patients with a duration of Parkinson's disease of at least 3 years, who meet all other entry criteria, will be considered for enrollment, with approval of the CRO Medical Monitor.
  • Patients must have a Hoehn and Yahr stage of I-IV during an "off" phase.
  • Patients should be levodopa responsive and must have been receiving treatment with a stable dose of levodopa [4-10 doses per day of any levodopa preparation (including CR, IR or a combination of CR/IR), plus benserazide/carbidopa; with or without addition of a COMT inhibitor] and may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic at the screening visit. Patients will receive the study medication as add-on therapy starting at baseline.
  • Patients should have motor fluctuations, with >1.5 hours "off" time during the day.
  • Patients must be able to maintain an accurate and complete diary (18-hour), with the help of a caregiver, recording "on" time, "on" time with minor dyskinesia, "on" time with troublesome dyskinesia, "off" time, and time asleep.
  • Patients must be able to understand and willing to sign an approved Informed Consent form.

Exclusion Criteria:

  • The patient has any indication of forms of parkinsonism other than idiopathic Parkinson's disease.
  • If female, the patient is of childbearing potential, pregnant or lactating.
  • The patient is in a late stage of Parkinson's disease, and is experiencing severe, disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms.
  • The patient has a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months.
  • The patient has a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including acute gastric ulcer, hypertension that is not well-controlled, asthma, chronic obstructive pulmonary disease (COPD), and Type I diabetes. Patients with a history of gastric ulcer who have not had an episode of acute gastritis in the last 6 months and are not currently experiencing gastric pain will be eligible for inclusion.
  • The patient has second- or third-degree atrio-ventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or a significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method.
  • The patient has participated in a previous clinical trial with safinamide.
  • The patient has a concomitant disease likely to interfere with the study medication (e.g. capable of altering absorption, metabolism or elimination of the study drug).
  • The patient has a history of psychosis (e.g. schizophrenia or psychotic depression), either previously or currently, or a score ≥ 3 on Item 2 (thought disorder) or 3 (depression) of the UPDRS Section I.
  • The patient has evidence of dementia or cognitive dysfunction, as indicated by a MMSE score < 22, or a score ≥ 3 on item 1 (mentation) of the UPDRS, Section I.
  • The patient is depressed, as indicated by a GRID-HAMD (17-item scale) score > 17.
  • The patient has a history of allergic response to anticonvulsants, levodopa, or other anti-parkinsonian agents.
  • The patient has a mental or physical condition (e.g., neurotic behaviour, crippling degenerative arthritis, or limb amputation), which would preclude performing efficacy or safety assessments.
  • The patient has hypersenstivity or contraindications to MAO B inhibitors.
  • The patient has a current history of severe dizziness or fainting on standing, due to postural hypotension.
  • The patient has a neoplastic disorder, which is either currently active or has been in remission for less than one year.
  • The patient has had stereotactic surgery as a treatment for his/her Parkinson's disease.
  • The patient has participated in a previous clinical trial within 30 days of entry into the study (screening visit) or has received treatment with any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to screening. The use of an investigational drug other than safinamide during the study is not permitted.
  • The patient is receiving treatment of his/her depression with a MAO inhibitor (e.g., selegiline), a tricyclic, or an SNRI (e.g., venlafaxine, duloxetine) at the screening visit. Note: Use of SSRIs will be permitted, provided the dose is kept as low as possible and remains stable throughout the trial.
  • The patient is receiving treatment of his/her parkinsonian symptoms with a MAO inhibitor. Note: Patients receiving amantadine, COMT inhibitors, DA agonists and/or anticholinergics will be eligible to enter the trial, provided they are on a stable dose at screening.
  • The patient has received treatment with any agent known to significantly inhibit or induce drug-metabolizing enyzmes (e.g., barbiturates, phenothiazines, etc.) within 4 weeks preceding the screening visit.
  • The patient has received treatment with opioids (e.g., tramadol, meperidine derivatives), in the 4 weeks prior to the screening visit.
  • The patient has received treatment with a depot neuroleptic within one injection cycle, or oral neuroleptics within 4 weeks prior to the screening visit. Patients who are receiving a low dose of an oral neuroleptic for treatment of psychotic symptoms (e.g., hallucinations) related to their Parkinson's disease or anti-parkinsonian medication, and who meet all other entry criteria, will be considered for enrollment, with approval of the CRO Medical Monitor. The Investigator must agree not to increase the dose of the oral neuroleptic during the trial, unless required for significant worsening.
  • The patient has received treatment with a drug that has hepatotoxic potential, e.g., tamoxifen, within 4 weeks, or received radiation therapy or a drug with cytotoxic potential, e.g, chemotherapy, within one year prior to the screening visit.
  • The patient has a history or a current diagnosis of HIV, tests positive for Hepatitis B surface antigen, tests positive for Hepatitis B core antibody, but negative for Hepatitis B surface antibody, or tests positive for Hepatitis C antibodies.
  • The patient has any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or a diagnostic laboratory test.
  • In the judgment of the Clinical Investigator the patient is likely to be non-compliant or uncooperative during the study.
  • Ophthalmologic history including any of the following conditions: albino patients, family history of hereditary retinal disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular inflammation (uveitis), or progressive, severe diabetic retinopathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01187966

Sponsors and Collaborators
Newron Sweden AB
Investigators
Principal Investigator: Mohit Bhatt, MD Jaslok Hospital, Mumbai
Principal Investigator: Neeta Mehta, MD J.J Hospital, Mumbai
Principal Investigator: Sankhla Charulata, MD P.D. Hinduja Hospital, Mumbai
Principal Investigator: Ajit Sowani, MD Neurology Centre, Ahmedabad
Principal Investigator: Prosenjit Chakraborty, MD Roby General Hospital, Kolkata
Principal Investigator: Sudhir Kothari, MD Poona Hospital, Pune
Principal Investigator: Sunil Bandishti, MD Ruby Hall Clinic, Pune
Principal Investigator: CU Velmurugendran, MD Sri Ramachandra Medical College, Chennai
Principal Investigator: Suresh Kumar, MD Vijaya Health Centre, Chennai
Principal Investigator: Devanathan Vasudevan, MD Kamakshi Memorial Hospital, Chennai
Principal Investigator: Rupam Borgohain, MD Nizams Institute of Medical Sciences, Hyderabad
Principal Investigator: J.K Murthy, MD CARE Hospital, Hyderabad
Principal Investigator: Vavilikolanu Prasad, MD Owasis Hospital & Research Centre, Hyderabad
Principal Investigator: Subashini Prabhakar, MD Spectra Clinical Research Centre, Hyderabad
Principal Investigator: Keshava Belur, MD J.S.S. Hospital Agrahara, Mysore
Principal Investigator: Pramod Pal, MD NIMHANS, Bangalore
Principal Investigator: Ajit Kumar Roy, MD St. Johns Medical College and Hospital, Bangalore
Principal Investigator: Rangashetti Srinivasa, MD M.S. Ramaiah Memoria Hospital, Bangalore
Principal Investigator: Arun B Shah, MD T.N.M.C and B.Y.L Nair Hospital, Mumbai
Principal Investigator: Krishnan Vijayan, MD Kovai Medical Centre and Hospital, Coimbatore
Principal Investigator: Neeta Mehta, MD Neeta Mehta's Clinic, Mumbai
Principal Investigator: Chandrashekhar Meshram, MD Brain and Mind Institute, Nagpur
Principal Investigator: Nellikunja Shankar, MD Mallikatta Neuro and Research Centre, Mangalore
Principal Investigator: Asha Kishore, MD Sree Chitra Tirual Institute for Sciences and Technology, Kerela
Principal Investigator: Ummer Karadan, MD Baby Memorial Hospital, Calicut
Principal Investigator: Mohammad I Sahadulla, MD Kerala Institute of Medical Sciences, Trivandrum
Principal Investigator: Madhuri Behari, MD All India Institute of Medical Sciences, New Delhi
Principal Investigator: Prahlad K Sethi, MD Sir Ganga Ram Hospital, New Delhi
Principal Investigator: Shamsher Dwivedee, MD Vidyasagar Institute of Mental Health and Neurosciences, New Delhi
Principal Investigator: Mukul Varma, MD Indraprastha Apollo Hospital, New Delhi
Principal Investigator: Rajinder Bansal, MD Dayanand Medical College and Hospital, Ludhiana
Principal Investigator: Sudesh Prabhakar, MD Post Grad Institute of Medical Education,& Research Dept of Neurology, Chandigarh
Principal Investigator: Sunil Pradhan, MD Institute of Human Behaviour and Allied Sciences, Dilshad Garden Delhi
Principal Investigator: Rakesh Shukla, MD Chhatrapati Sahuji Maharaj Medical University, Lucknow
Principal Investigator: Pahari Ghosh, MD Sri Aurbindo Seva Kendra, Kolkata
Principal Investigator: Ovidiu Bajenaru, MD University Hospital of Emergency Hospital, Bucuresti
Principal Investigator: Cristina Panea, MD Elias University Hospital, Bucuresti
Principal Investigator: Ana Campeanu, MD Fundeni Hospital, Bucuresti
Principal Investigator: Marina Ticmeanu, MD colentina Hospital, Bucuresti
Principal Investigator: Dafin Muresanu, MD Emergency Hospital Cluj, Cluj
Principal Investigator: Angelo Bulboaca, MD Rehabilitation Hospital Cluj, Cluj
Principal Investigator: Jozsef Szasz, MD Emergency Hospital Targu-Mures, Targu Mures
Principal Investigator: Cristian Dinu Popescu, MD Rehabiliation Hospital Iasi, Iasi
Principal Investigator: Mihaela Simu, MD Emergency Hospital Timisoara no. 1, Timisoara
Principal Investigator: Dana Chirileanu, MD Emergency Hospital Timisoara no.1, Timisoara
Principal Investigator: Roberto Eleopra, MD Ospedale dell'Angelo, Venezia
Principal Investigator: Rocco Quatrale, MD Arcispedale S. Anna, Ferrara
Principal Investigator: Marco Onofri, MD Centro dell'invecchiamento, Chieti
Principal Investigator: Tanina Pia Avarello, MD Centro di Riferimento Regionale Malattie Extra Piramidali, Palermo
Principal Investigator: Ubaldo Bonuccelli, MD Ospedale di Viareggio, Viareggio
Principal Investigator: Giovanni Fabbrini, MD Dip. Scienze Neurologiche, Roma
Principal Investigator: Paolo Stanzione, MD Policlinico Tor Vergata, Roma
Principal Investigator: Fabrizio Stocchi, MD IRCCS S. Raffaele Pisana, Roma
  More Information

Additional Information:
No publications provided

Responsible Party: Dr Ravi Anand CMO, Newron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01187966     History of Changes
Other Study ID Numbers: NW-1015/016/III/2006
Study First Received: May 31, 2010
Last Updated: August 23, 2010
Health Authority: India: Drugs Controller General of India
Romania: National Medicines Agency
Italy: Ministry of Health

Keywords provided by Newron Sweden AB:
Parkinson's Disease
PD
Levodopa
Patients with idiopathic Parkinson's disease with motor fluctuations

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on July 22, 2014